Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Role of steatotic liver disease in prediction and prevention of cardiometabolic diseases

Nature Reviews Gastroenterology & Hepatology volume 21, pages 136–137 (2024)Cite this article

Subjects

Steatotic liver disease has emerged as an important risk factor for cardiovascular disease, type 2 diabetes mellitus and chronic kidney disease. Successful treatment of steatotic liver disease might also be effective in preventing these cardiometabolic diseases.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Hepatic steatosis.

References

  1. Roden, M. & Shulman, G. I. The integrative biology of type 2 diabetes. Nature 576, 51–60 (2019).

    Article  CAS  PubMed  ADS  Google Scholar 

  2. Targher, G., Tilg, H. & Byrne, C. D. Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach. Lancet Gastroenterol. Hepatol. 6, 578–588 (2021).

    Article  PubMed  Google Scholar 

  3. Rinella, M. E. et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology https://doi.org/10.1016/j.aohep.2023.101133 (2024).

    Article  PubMed  Google Scholar 

  4. Ren, Z., Simons, P. I. H. G., Wesselius, A., Stehouwer, C. D. A. & Brouwers, M. C. G. J. Relationship between NAFLD and coronary artery disease: a Mendelian randomization study. Hepatology 77, 230–238 (2023).

    Article  PubMed  Google Scholar 

  5. Stefan, N., Schick, F., Birkenfeld, A. L., Häring, H.-U. & White, M. F. The role of hepatokines in NAFLD. Cell Metab. 35, 236–252 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Cao, Y. et al. Liver–heart cross-talk mediated by coagulation factor XI protects against heart failure. Science 377, 1399–1406 (2022).

    Article  CAS  PubMed  PubMed Central  ADS  Google Scholar 

  7. Aminian, A. et al. Association of bariatric surgery with major adverse liver and cardiovascular outcomes in patients with biopsy-proven nonalcoholic steatohepatitis. JAMA 326, 2031–2042 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  8. Harrison, S. A., Allen, A. M., Dubourg, J., Noureddin, M. & Alkhouri, N. Challenges and opportunities in NASH drug development. Nat. Med. 29, 562–573 (2023).

    Article  CAS  PubMed  Google Scholar 

  9. Mantovani, A., Byrne, C. D. & Targher, G. Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium–glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review. Lancet Gastroenterol. Hepatol. 7, 367–378 (2022).

    Article  PubMed  Google Scholar 

  10. Loomba, R. et al. Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH. N. Engl. J. Med. 389, 998–1008 (2023).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Author notes

  1. These authors contributed equally: Norbert Stefan, Amedeo Lonardo, Giovanni Targher.

Authors and Affiliations

  1. Department of Internal Medicine IV, Division of Endocrinology, Diabetology and Nephrology, University of Tübingen, Tübingen, Germany

    Norbert Stefan

  2. Institute of Diabetes Research and Metabolic Diseases (IDM) of the Helmholtz Center Munich, Tübingen, Germany

    Norbert Stefan

  3. Department of Internal Medicine, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy

    Amedeo Lonardo

  4. Department of Medicine, Section of Endocrinology, Diabetes, and Metabolism, University of Verona, Verona, Italy

    Giovanni Targher

  5. Metabolic Diseases Research Unit, IRCCS Sacro Cuore – Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy

    Giovanni Targher

Authors
  1. Norbert Stefan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Amedeo Lonardo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Giovanni Targher
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Norbert Stefan.

Ethics declarations

Competing interests

N.S. declares that he has received speaker honoraria from AstraZeneca, Boehringer-Ingelheim, Bristol Myers Squibb, Genkyotex, Intercept Pharma, Lilly, Merck Sharp & Dohme, Novo Nordisk, Pfizer and Sanofi, has received research funding from AstraZeneca, DSM Nutritional Products, F. Hoffmann-La Roche and Sanofi, and has acted as an advisor for AstraZeneca, Genkyotex, GlaxoSmithKline Biologicals, Intercept Pharma, Lilly, Novo Nordisk, Pfizer and Sanofi. The other authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Stefan, N., Lonardo, A. & Targher, G. Role of steatotic liver disease in prediction and prevention of cardiometabolic diseases. Nat Rev Gastroenterol Hepatol 21, 136–137 (2024). https://doi.org/10.1038/s41575-023-00880-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41575-023-00880-2

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing